JP2009504774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504774A5 JP2009504774A5 JP2008527161A JP2008527161A JP2009504774A5 JP 2009504774 A5 JP2009504774 A5 JP 2009504774A5 JP 2008527161 A JP2008527161 A JP 2008527161A JP 2008527161 A JP2008527161 A JP 2008527161A JP 2009504774 A5 JP2009504774 A5 JP 2009504774A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- administered
- use according
- saha
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 16
- 229960000237 vorinostat Drugs 0.000 claims 16
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 11
- 229940099419 targretin Drugs 0.000 claims 7
- 238000011260 co-administration Methods 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 4
- 150000004492 retinoid derivatives Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 229940034208 thyroxine Drugs 0.000 claims 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70959905P | 2005-08-18 | 2005-08-18 | |
| US73375205P | 2005-11-04 | 2005-11-04 | |
| PCT/US2006/032282 WO2007022408A2 (en) | 2005-08-18 | 2006-08-18 | Combination methods of saha and targretin for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504774A JP2009504774A (ja) | 2009-02-05 |
| JP2009504774A5 true JP2009504774A5 (enExample) | 2009-09-10 |
Family
ID=37758430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008527161A Withdrawn JP2009504774A (ja) | 2005-08-18 | 2006-08-18 | 癌を治療するためにｓａｈａ及びターグレチンの併用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090227674A1 (enExample) |
| EP (1) | EP1933825A2 (enExample) |
| JP (1) | JP2009504774A (enExample) |
| AU (1) | AU2006279400A1 (enExample) |
| CA (1) | CA2617623A1 (enExample) |
| WO (1) | WO2007022408A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04008577A (es) | 2002-03-04 | 2005-07-13 | Aton Pharma Inc | Metodos para inducir diferenciacion terminal. |
| TWI365068B (en) | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| LT1937244T (lt) | 2005-09-30 | 2018-11-12 | Io Therapeutics, Llc | Vėžio gydymas specifiniais rxr agonistais |
| PL2148676T3 (pl) * | 2007-04-25 | 2016-12-30 | Stosowanie sapacytabiny do leczenia choroby proliferacyjnej | |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| CN110151745A (zh) | 2011-12-13 | 2019-08-23 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
| EP3076973B1 (en) * | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| US20170079942A1 (en) * | 2014-05-21 | 2017-03-23 | National Institute Of Advanced Industrial Science And Technology | Cancer stem cell proliferation inhibitor |
| WO2016164770A1 (en) * | 2015-04-10 | 2016-10-13 | Bioresponse, L.L.C. | Self-emulsifying formulations of dim-related indoles |
| KR102149321B1 (ko) | 2015-10-31 | 2020-08-28 | 아이오 테라퓨틱스, 인크. | Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료 |
| KR102549273B1 (ko) | 2016-03-10 | 2023-06-28 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료 |
| NZ745704A (en) * | 2016-03-10 | 2019-04-26 | Io Therapeutics Inc | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
| WO2018089861A1 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Methods and compositions for the treatment of cancer and metabolic diseases |
| EP3684348A4 (en) | 2017-09-20 | 2021-08-18 | IO Therapeutics, Inc. | TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS |
| WO2020232399A1 (en) * | 2019-05-16 | 2020-11-19 | The Regents Of The University Of California | Compositions comprising hdac inhibitors and retinoids |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| EP4444287A4 (en) | 2021-12-07 | 2025-05-28 | Io Therapeutics, Inc. | USE OF AN RXR AGONIST AND TAXANES FOR THE TREATMENT OF HER2+ CANCER |
| KR20240115316A (ko) | 2021-12-07 | 2024-07-25 | 아이오 테라퓨틱스, 인크. | 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060430A1 (en) * | 2001-02-01 | 2002-08-08 | Cornell Research Foundation, Inc. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
-
2006
- 2006-08-18 WO PCT/US2006/032282 patent/WO2007022408A2/en not_active Ceased
- 2006-08-18 AU AU2006279400A patent/AU2006279400A1/en not_active Abandoned
- 2006-08-18 US US11/990,724 patent/US20090227674A1/en not_active Abandoned
- 2006-08-18 JP JP2008527161A patent/JP2009504774A/ja not_active Withdrawn
- 2006-08-18 EP EP06813528A patent/EP1933825A2/en not_active Withdrawn
- 2006-08-18 CA CA002617623A patent/CA2617623A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8410092B2 (en) | Two-component pharmaceutical composition for the treatment of pain | |
| JP2021063088A5 (enExample) | ||
| JP2006504795A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2022537551A5 (enExample) | ||
| JP2009514874A5 (enExample) | ||
| JP2015512406A5 (enExample) | ||
| JP2005512995A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JPH01503539A (ja) | 非鎮静抗ヒスタミン薬を含んでなる咳／風邪用混合物 | |
| JP2009522370A5 (enExample) | ||
| JPWO2023027198A5 (enExample) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2010521417A5 (enExample) | ||
| JP2009501801A5 (enExample) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2023531675A5 (enExample) | ||
| JP2008533127A5 (enExample) | ||
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| JP2020515523A5 (enExample) | ||
| JP2001515041A5 (enExample) | ||
| JP2022517902A5 (enExample) | ||
| JP2023549849A5 (enExample) | ||
| JP2005519936A5 (enExample) |